The global Non-Hodgkin Lymphoma therapeutics market size stood at around USD XX billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 7.4% during the forecast period.
Lymphoma is one of the most hazardous and life threatening type of cancer, related to lymphocytes, an important type of white blood cells. Non-Hodgkin’s lymphomas (NHL) is a distinct group of blood cancer, which includes large variety of lymphomas, excluding Hodgkin’s lymphomas. Non-Hodgkin’s lymphoma (NHL) varies in their severity, from mild to fatal.
Market Drivers and Restraints
Certain factors that are driving the market growth include a rise in the prevalence of NHL, demand for innovative drugs and novel technologies, and an increase in the number of FDA approvals for NHL therapy drugs. In addition, an increase in public awareness about NHL, robust drug pipeline for the treatment of the disease, improved diagnostic techniques to detect NHL, and an increase in the prevalence of non-Hodgkin lymphoma are the factors fueling the NHL therapeutics market across the world. However, the high cost of NHL drugs and various complications associated with them are acting as major restraints for the non-Hodgkin lymphoma therapeutics market.
Additionally, stringent regulatory guidelines are limiting the growth of the market.